Property | Value |
?:abstract
|
-
COVID-19 caused by SARS-COV2 infection can lead to multi-organ injuries and significant mortality in severe and critical patients, especially among those individuals with type 2 diabetes (T2D) as a comorbidity. While attenuated mortality was observed with aggressive glucose control, it was unclear whether therapeutic regiments including insulin treatment was beneficial for patients with COVID-19 and T2D. This retrospective study investigated 689 patients with COVID-19 and T2D from a cohort of 3,305 cases from Wuhan, China. Unexpectedly, we found that insulin treatment for patients with COVID-19 and T2D was associated with a significant increase in mortality [27.2% vs. 3.5%; adjusted HR, 5.38 (2.75-10.54)]. Further analysis showed that insulin treatment was associated with enhanced systemic inflammation and aggravated injuries of vital organs. Therefore, insulin treatment for patients with COVID-19 and T2D should be used with caution.
|
is
?:annotates
of
|
|
?:creator
|
|
?:doi
|
|
?:doi
|
-
10.1016/j.cmet.2020.11.014
|
?:journal
|
|
?:license
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/4f6ff3c77f64d85bdba55fdead6bcc13e57487da.json
|
?:pmcid
|
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
?:sha_id
|
|
?:source
|
|
?:title
|
-
Insulin treatment is associated with increased mortality in patients with COVID-19
|
?:type
|
|
?:year
|
|